U.S. Serial No. 09/284,424
Group Art Unit No. 1623

IN THE CLAIMS:

Please amend claims 1, 17, 18, 20 and 34 as follows:

(Thrice Amended) A compound of the Formula I



I

wherein R^1 is R^3OC-,
R^3CO-,
R^3SO_2-,





,



,



,



, or



;

each R^a is independently hydrogen, C_1-C_6 alkyl, or -$(CH_2)_n$ aryl;

R^2 is -$(CRR)_n$-aryl,
-$(CRR)_n$-X-aryl,
-$(CRR)_n$-(substituted-aryl),

-(CRR)$_n$-X-(substituted-aryl),
-(CRR)$_n$-aryl-aryl,
-(CRR)$_n$-aryl-(CH$_2$)$_n$-aryl,
-(CRR)$_n$-CH(aryl)2,
-(CRR)$_n$-cycloalkyl,
-(CRR)$_n$-X-cycloalkyl,

—(CRR)$_n$—CH[(CH$_2$)$_n$—aryl][(CH$_2$)$_n$—aryl] ,

—(CRR)$_n$—CH[(CH$_2$)$_n$—substituted aryl][(CH$_2$)$_n$—aryl] ,


,

—(CRR)$_n$ CH(aryl)(NH aryl) ,


,


,


,

C1 cont'd



,



, or



or



;

Cont'd

each R is independently hydrogen, C_1-C_6 alkyl, halogen or hydroxy;
X is O or S;
R^3 is C_1-C_6 alkyl,
aryl,
-$(CHR)_n$-aryl,
-$(CHR)_n$-substituted aryl,

-$(CRR)_n$COR^a,
-$(CRR)_n$O$(CH_2)_n$-aryl,
cycloalkyl,
substituted cycloalkyl,

-$(CRR)_n$CNR^{a}R^a,



C' l
cont'd



each R′ is independently C_1-C_6 alkyl,
C_1-C_6 alkylaryl,
aryl, or
hydrogen;

each J is independently
-NH-SO_2-(C_1-C_6-alkyl),
$-CO_2R^b$,
$-CONR^bR^b$,
$-SO_2NR^bR^b$, or
$-SO_2R^b$;

each R^b is independently hydrogen, C_1-C_6 alkyl, aryl, substituted aryl, arylalkyl, or substituted arylalkyl;

R^4 is hydrogen,
C_1-C_6 alkyl,
$CH_3OC(=O)$-,
-phenyl, or
C_1-C_6 alkyl $C(=O)$-;

R^5 is C_1-C_6 alkyl-CO-,
$-(CH_2)_n$ aryl,
C_1-C_6-alkyl$OC(=O)$-,
C_1-C_6-alkyl-X-$(CH_2)_nCO$,
C_1-C_6-alkyl-X-$(CH_2)_nOC(=O)$-,

C'd cont'd



R^{5a} is

cont'd



$-C(O)-CH(-(CH_2)_n-\text{aryl or substituted aryl})-NHC(O)C_1\text{-}C_6$ alkyl,

$CO(CH_2)_n$ aryl, or

$C(O)(CH_2)_n$ aryl;

R^6 is hydrogen,
C_1-C_6 alkyl, $-(CH_2)_n$ aryl, $-(CH_2)_nCO_2R^a$, or hydroxyl substituted C_1-C_6 alkyl;

R^7 is hydrogen, $-S-(C_1-C_6\text{-alkyl})$, or $-SO_2-(C_1-C_6\text{-alkyl})$;

each n is independently 0 to 3, and the pharmaceutically acceptable, salts, esters, amides, and prodrugs thereof;

excluding the following compounds:

N-Benzyloxycarbonyl-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Benzyloxycarbony-L-aspartic acid 2,6-ditrifluoromethyl benzoyloxymethyl ketone;
N-Benzyloxycarbonyl-L-aspartic acid 2,6-dichloro-3-(2-N-morpholinylethoxy)benzoyloxymethyl ketone;
N-Benzyloxycarbonyl-L-aspartic acid 2,6-dimethoxybenzoyloxy methyl ketone;
N-Benzyloxycarbonyl-L-aspartic acid 2,-dichloro-3-(benzyloxy)benzoyloxymethyl ketone;
N-Benzyloxycarbonyl-L-aspartic acid 2-acetamido-6-chlorobenzoyloxymethyl ketone;
N-Benzyloxycarbonyl-L-aspartic acid 2,6-difluorobenzoyloxymethyl ketone;
N-Benzyloxycarbonyl-L-aspartic acid 3-(N-butylsulfonamido)-2,6-dichlorobenzoyloxymethyl ketone;
N-Benzyloxycarbonyl-L-aspartic acid 2,6-dichloro-3-sulfonamido benzoyloxymethyl ketone;
N-Benzyloxycarbonyl-L-aspartic acid 3-(N-benzylsulfonamido)-2,6-dichlorobenzoyloxymethyl ketone;
N-Benzyloxycarbonyl-L-aspartic acid 3-(N-(2-aminoacetamidoyl)-sulfonamido)-2,6-dichlorobenzoyloxymethyl ketone;
N-Benzyloxycarbonyl-L-aspartic acid 2,6-dichloro-3-(N-morpholinylsulfonamido)benzoyloxymethyl ketone;
N-Methoxycarbonyl-L-alanine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-(2-thienyl)carbonyl-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;

Cl
Cont'd

N-Methoxycarbonyl glycine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Methoxycarbonyl-L-phenylalanine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Methoxycarbonyl-L-valine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Methoxycarbonyl-L-histidine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Benzyloxycarbonyl-L-valine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Benzyloxycarbonyl-L-alanine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Benzyloxycarbonyl-L-valine-L-alanine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-(2-Furonyl)carbonyl-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-(2-Furonyl)carbonyl-L-aspartic acid 2,6-dichloro-3-(N-morpholinylsulfonamido)benzoyloxymethyl ketone;
N-(3-Phenylpropionyl)-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Methoxycarbonyl-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-(4-N,N-dimethylaminomethyl)benzoyl-L-aspartic acid 2,6-diclorobenzoloxymethyl ketone;
N-Benzyloxycarbonyl-D-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Methoxy-L-histidine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Methoxy-glycine -L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Methoxy-L-alanine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Methoxy-L-valine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Benzyloxy-L-valine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Benzyloxy-D-alanine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Benzyloxy-L-alanine-L-alanine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Benzyloxy-L-valine-L-alanine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Benzyloxy-D-alanine-L-alanine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-(N-phenylpropionyl-valinyl-alaninyl)-3-amino-4-oxo-5-(2,6-bistrifluoro methylbenzoyloxy) pentanoic acid;
N-(N-phenylpropionyl-valinyl-alaninyl)-3-amino-4-oxo-5-benzoyloxy pentanoic acid;
N-(N-Acetyl-tyrosinyl-valinyl-alaninyl)-3-amino-4-oxo-5-(pentafluorobenz oyloxy) pentanoic acid;
3-Phenylpropionyl-L-valine-L-alanine-aspartic acid 2-phenylethylcarbonyloxymethyl ketone;
Adamantane-1-carboxylic acid 3-[2-(2-benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-4-carboxy-2-oxo-butyl ester;
Acridine-9-carboxylic acid 3-[2-(2-benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-4-carboxy-2-oxo-butyl ester;
1H-Indole-3-carboxylic acid 3-[2-(2-benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-4-carboxy-2-oxo-butyl ester;
2-Methyl-imidazo[1,2-a]pyridine-3-carboxylic acid 3-[2-(2-benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-4-carboxy-2-oxo-butyl ester;
2-Methoxy-3-methyl-quinoline-4-carboxylic acid 3-[2-(2-benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-4-carboxy-2-oxo-butyl ester;
1,3-Dimethyl-1H-indole-2-carboxylic acid 3-[2-(2-benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-4-carboxy-2-oxo-butyl ester;

C1 cont'd

9H-Xanthene-9-carboxylic acid 3-[2-(2-benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-4-carboxy-2-oxo-butyl ester;
3-[2-(2-Benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-5-diphenylacetoxy-4-oxo-pentanoic acid;
2,6-Dichloro-benzoic acid 3-(5-benzyloxycarbonylamino-naphthalene-1-sulfonylamino)-4-carboxy-2-oxo-butyl ester;
2,6-Dichloro-benzoic acid 3-{[2-(1-benzyloxycarbonylamino-2-methyl-propyl)-thiazole-4-carbonyl]-amino}-4-carboxy-2-oxo-butyl ester;
2,6-Dichloro-benzoic acid 3-[2-(3-benzyloxycarbonylamino-phenyl)-propionylamino]-4-carboxy-2-oxo-butyl ester;
2,6-Dichloro-benzoic acid 3-[(5-benzyloxycarbonylamino-1H-indole-3-carbonyl)-amino]-4-carboxy-2-oxo-butyl ester;
2,6-Dichloro-benzoic acid 3-[2-(6-benzyloxycarbonyloxy-naphthalen-2-yl)-propionylamino]-4-carboxy-2-oxo-butyl ester;
2,6-Dichloro-benzoic acid 3-(5-benzyloxycarbonylamino-naphthalene-1-sulfonylamino)-4-carboxy-2-oxo-butyl ester;
2,6-Dichloro-benzoic acid 3-[(5-benzyloxycarbonylamino-naphthalene-1-carbonyl)-amino]-4-carboxy-2-oxo-butyl ester;
2,6-Dichloro-benzoic acid 3-[(6-benzyloxycarbonylamino-5-oxo-octahydro-indolizine-3-carbonyl)-amino]-4-carboxy-2-oxo-butyl ester; and
2,6-Dichloro-benzoic acid 3-[(4-benzyloxycarbonylamino-cyclohexanecarbonyl)-amino]-4-carboxy-2-oxo-butyl ester.

C1 cancld

17. (Amended) A compound according to Claim 1 wherein each R^a is hydrogen; R^1 is benzyloxycarbonyl; R^2 is aryl-X$(CRR)_n$-, aryl-$(CRR)_n$-, or cycloalkyl-$(CRR)_n$-; n is 1, 2, or 3; X is O or S; and R is hydrogen, methyl, or benzyl.

C2

18. (Amended) A compound according to Claim 1 wherein each R^a is hydrogen;

R^1 is benzyloxycarbonyl; and

R^3 is -$(CH_2)_n$-naphthyl,

-$(CH_2)_n$-phenyl,

-$(CH_2)_n$-cycloalkyl,

-$(CH_2)_n O(CH_2)_n$-naphthyl,

-$(CH_2)_n O(CH_2)_n$-phenyl, or

-$(CH_2)_n S(CH_2)_n$-phenyl.

20. (Twice Amended) A compound in accordance with Claim 1 wherein each R^a is hydrogen; and

R^1 is benzyloxycarbonyl,



,



,



, or



.

34. (Amended) The compounds:

(S)-5-(Naphthalene-1-yl-acetoxy)-4-oxo-3-phenylacetylamino-pentanoic acid;
3-[(2-Carbamoyl-cyclopentanecarbonyl)-amino]-5-(naphthalen-1-yl-acetoxy)-4-oxo-pentanoic acid;
3-[(3-Carbamoyl-bicyclo[2.2.1]heptane-2-carbonyl)-amino]-5-(naphthalen-1-yl-acetoxy)-4-oxo-pentanoic acid;
3-(3-Methanesulfonyl-2-methyl-propionylamino)-5-(naphthalen-1-yl-acetoxy)-4-oxo-pentanoic acid;
3-(3-Benzenesulfonyl-2-methyl-propionylamino)-5-(naphthalen-1-yl-acetoxy)-4-oxo-pentanoic acid;
3-Butyrylamino-5-(naphthalen-2-yl-acetoxy)-4-oxo-pentanoic acid;
3-Acetylamino-5-(naphthalen-1-yl-acetoxy)-4-oxo-pentanoic acid;
3-(3-Methanesulfonyl-2-methyl-propionylamino)-5-(naphthalen-1-yl-acetoxy)-4-oxo-pentanoic acid;
3-(3-Methyl-butyrylamino)-5-(naphthalen-1-yl-acetoxy)-4-oxo-pentanoic acid;

U.S. Serial No. 09/284,424
Group Art Unit No. 1623

3-(3-Carbamoyl-propionylamino)-5-(naphthalen-1-yl-acetoxy)-4-oxo-pentanoic acid;

[S-(R*,R*)]-3-(3-Acetylsulfanyl-2-methyl-propionylamino)-5-(naphthalen-1-yl-acetoxy)-4-oxo-pentanoic acid; and

trans-3-[(3-Carbamoyl-cyclopentanecarbonyl)-amino]-5-(naphthalen-1-yl-acetoxy)-4-oxo-pentanoic acid.

Please add new claims 52 – 54 as follows:

52. (New) A compound of the Formula I



I

wherein R^1 is R^3OC-,
R^3CO-,
R^3SO_2-,


,

,


,

, or

;

each R^a is independently hydrogen, C_1-C_6 alkyl, or -$(CH_2)_n$ aryl;

R^2 is -$(CRR)_n$-aryl,

$-(CRR)_n$-X-aryl,

$-(CRR)_n$-(substituted-aryl), provided that the aryl group is not substituted with alkoxy, halogen, or trifluoromethyl,

$-(CRR)_n$-X-(substituted-aryl),

$-(CRR)_n$-aryl-aryl,

$-(CRR)_n$-aryl-$(CH_2)_n$-aryl,

$-(CRR)_n$-CH(aryl)$_2$,

$-(CRR)_n$-cycloalkyl,

$-(CRR)_n$-X-cycloalkyl,



,



,



,

C5 cont'd



,



,



,



,



,



, or



or



;

C5 cont'd

each R is independently hydrogen, C_1-C_6 alkyl, halogen or hydroxy;
X is O or S;
R^3 is C_1-C_6 alkyl,
aryl,
-$(CHR)_n$-aryl,
-$(CHR)_n$-substituted aryl,

-$(CRR)_nCOR^a$,
-$(CRR)_nO(CH_2)_n$-aryl,
cycloalkyl,
substituted cycloalkyl,

-$(CRR)_nCNR^aR^a$, .

U.S. Serial No. 09/284,424
Group Art Unit No. 1623



C5 cont'd



each R′ is independently C_1-C_6 alkyl,
C_1-C_6 alkylaryl,
aryl, or
hydrogen;

each J is independently
-NH-SO_2-(C_1-C_6-alkyl),
$-CO_2R^b$,
$-CONR^bR^b$,
$-SO_2NR^bR^b$, or
$-SO_2R^b$;

each R^b is independently hydrogen, C_1-C_6 alkyl, aryl, substituted aryl, arylalkyl, or substituted arylalkyl;

R^4 is hydrogen,
C_1-C_6 alkyl,
$CH_3OC(=O)$-,
-phenyl, or
C_1-C_6 alkyl $C(=O)$-;

R^5 is C_1-C_6 alkyl-CO-,
$-(CH_2)_n$ aryl,
C_1-C_6-alkyl$OC(=O)$-,
C_1-C_6-alkyl-X-$(CH_2)_nCO$,
C_1-C_6-alkyl-X-$(CH_2)_nOC(=O)$-,

C5 cont'd

U.S. Serial No. 09/284,424
Group Art Unit No. 1623



C5 cont'd



$-\overset{O}{\overset{\|}{C}}-CH(CH_2)_n-NHC\overset{O}{\overset{\|}{C}}C_1\text{-}C_6$ alkyl,

aryl or substituted aryl,

$CO(CH_2)_n$ aryl,

$C(CH_2)_n$ aryl;

R^6 is hydrogen,

C_1-C_6 alkyl, $-(CH_2)_n$ aryl, $-(CH_2)_nCO_2R^a$, or hydroxyl substituted C_1-C_6 alkyl;

R^7 is hydrogen, $-S-(C_1-C_6\text{-alkyl})$, or $-SO_2-(C_1-C_6\text{-alkyl})$;

each n is independently 0 to 3,

provided that when R^{5a} is

$CO(CH_2)_n$ aryl,

then n is 0, 2, or 3, and

provided that when R^{5a} is

$C(CH_2)_n$ aryl,

then n is 0, 1, or 3,

and the pharmaceutically acceptable, salts, esters, amides, and prodrugs thereof.

C5 contd

53. (New) A compound of the Formula I

I

wherein R^1 is R^3OC-,

R^3CO-,
R^3SO_2-,
R^a
R^5NCHR^6CO-,


,

,

,

, or

;

each R^a is independently hydrogen, C_1-C_6 alkyl, or -$(CH_2)_n$ aryl;

R^2 is -$(CRR)_n$-aryl,
-$(CRR)_n$-X-aryl,
-$(CRR)_n$-X-(substituted-aryl),
-$(CRR)_n$-aryl-aryl,
-$(CRR)_n$-aryl-$(CH_2)_n$-aryl,
-$(CRR)_n$-CH(aryl)2,
-$(CRR)_n$-cycloalkyl,
-$(CRR)_n$-X-cycloalkyl,


,


,

C5 contd

U.S. Serial No. 09/284,424
Group Art Unit No. 1623

C5 contd





;

each R is independently hydrogen, C_1-C_6 alkyl, halogen or hydroxy;

X is O or S;

R^3 is C_1-C_6 alkyl,

aryl,

-$(CHR)_n$-aryl,

-$(CHR)_n$-substituted aryl,

-$(CRR)_n$$COR^a$,

-$(CRR)_nO(CH_2)_n$-aryl,

cycloalkyl,

substituted cycloalkyl,

-$(CRR)_n$$CNR^aR^a$,



-$(CRR)_n$-S-$(CH_2)_n$ aryl,

-$(CRR)_n$-SC_1-C_6 alkyl,



J-CH_2CH-,

-$(CRR)_n$S$(CH_2)_n$$COR^a$,

C5 cont'd

C5 contd



each R' is independently C_1-C_6 alkyl,
C_1-C_6 alkylaryl,
aryl, or
hydrogen;

each J is independently
-NH-SO_2-(C_1-C_6-alkyl),
-CO_2R^b,
-$CONR^bR^b$,
-$SO_2NR^bR^b$, or

$-SO_2R^b$;

each R^b is independently hydrogen, C_1-C_6 alkyl, aryl, substituted aryl, arylalkyl, or substituted arylalkyl;

R^4 is hydrogen,
C_1-C_6 alkyl,
CH_3OC-,
-phenyl, or
C_1-C_6 alkyl C-;

R^5 is C_1-C_6 alkyl-CO-,
$-(CH_2)_n$ aryl,
C_1-C_6-alkylOC-,
C_1-C_6-alkyl-X-$(CH_2)_nCO$,
C_1-C_6-alkyl-X-$(CH_2)_nOC$-,
$-C(CRR)_n$aryl,
$-CNR^aR^a$,
$-SC_1$-C_6 alkyl,
$-C(CH_2)_nCNR^aR^a$,
$-CO(CH_2)_n$ aryl,
$-CO(CH_2)_n$ substituted aryl,

C5 cont'd



$-C(CRR)_nNHCO(CH_2)_n$-aryl,

$-(CH_2)_nX(CH_2)_n$-aryl, or

$-C_1$-C_6 alkyl X-C_1-C_6 alkyl aryl;

R^{5a} is

CC_1-C_6 alkyl,

$-COC_1$-C_6 alkyl,

$-C$-CH-$NHCC_1$-C_6 alkyl,

$(CH_2)_n$

aryl or substituted aryl,

$CO(CH_2)_n$ aryl, or

$C(CH_2)_n$ aryl;

R^6 is hydrogen,

C_1-C_6 alkyl, $-(CH_2)_n$ aryl, $-(CH_2)_nCO_2R^a$, or hydroxyl substituted C_1-C_6 alkyl;

R^7 is hydrogen, $-S-(C_1-C_6\text{-alkyl})$, or $-SO_2-(C_1-C_6\text{-alkyl})$;

each n is independently 0 to 3,

provided that when R^{5a} is

$CO(CH_2)_n$ aryl,

then n is 0, 2, or 3, and

provided that when R^{5a} is

C5 cont'd

$C(CH_2)_n$ aryl,
then n is 0, 1, or 3,
and the pharmaceutically acceptable, salts, esters, amides, and prodrugs thereof.

54. (New) A compound of the Formula I



I

wherein R^1 is R^3OC-,
R^3CO-,
R^3SO_2-,





,



,



,



, or



;

each R^a is independently hydrogen, C_1-C_6 alkyl, or -$(CH_2)_n$ aryl;

R^2 is -$(CRR)_n$-aryl,
-$(CRR)_n$-X-aryl,

C5 contd

U.S. Serial No. 09/284,424
Group Art Unit No. 1623

C5 cont'd





,



, or



or



;

C5 cont'd

each R is independently hydrogen, C_1-C_6 alkyl, halogen or hydroxy;
X is O or S;
R^3 is C_1-C_6 alkyl,
aryl,
-$(CHR)_n$-aryl,
-$(CHR)_n$-substituted aryl,

-$(CRR)_nO(CH_2)_n$-aryl,
cycloalkyl,
substituted cycloalkyl,



C5 contd



each R′ is independently C_1-C_6 alkyl,
C_1-C_6 alkylaryl,
aryl, or
hydrogen;

each J is independently
-NH-SO_2-(C_1-C_6-alkyl),
$-CO_2R^b$,
$-CONR^bR^b$,
$-SO_2NR^bR^b$, or
$-SO_2R^b$;

each R^b is independently hydrogen, C_1-C_6 alkyl, aryl, substituted aryl, arylalkyl, or substituted arylalkyl;

R^4 is hydrogen,
C_1-C_6 alkyl,
$CH_3OC(=O)$-,
-phenyl, or
C_1-C_6 alkyl $C(=O)$-;

R^5 is C_1-C_6 alkyl-CO-,
$-(CH_2)_n$ aryl,
C_1-C_6-alkyl$OC(=O)$-,
C_1-C_6-alkyl-X-$(CH_2)_nCO_2$,
C_1-C_6-alkyl-X-$(CH_2)_nOC(=O)$-,

C5 cont'd

C5 contd



C5 concld



$-C(=O)-CH(-(CH_2)_n-\text{aryl or substituted aryl})-NHC(=O)C_1\text{-}C_6$ alkyl,

R^6 is hydrogen, C_1-C_6 alkyl, $-(CH_2)_n$ aryl, $-(CH_2)_nCO_2R^a$, or hydroxyl substituted C_1-C_6 alkyl;

R^7 is hydrogen, $-S-(C_1-C_6\text{-alkyl})$, or $-SO_2-(C_1-C_6\text{-alkyl})$;

each n is independently 0 to 3, and the pharmaceutically acceptable, salts, esters, amides, and prodrugs thereof.